In the last trading session, 1.33 million Biohaven Ltd (NYSE:BHVN) shares changed hands as the company’s beta touched 3.93. With the company’s per share price at $35.57 changed hands at -$1.91 or -5.10% during last session, the market valuation stood at $3.60B. BHVN’s last price was a discount, traded about -74.89% off its 52-week high of $62.21. The share price had its 52-week low at $26.80, which suggests the last value was 24.66% up since then. When we look at Biohaven Ltd’s average trading volume, we note the 10-day average is 1.06 million shares, with the 3-month average coming to 919.89K.
Analysts gave the Biohaven Ltd (BHVN) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.14. If we narrow down to specifics, the data shows that 0 out of 7 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended BHVN as a Hold, 7 felt it is a Buy and 0 rated the stock as Underweight. Biohaven Ltd’s EPS for the current quarter is expected to be -1.66.
Biohaven Ltd (NYSE:BHVN) trade information
Instantly BHVN was in red as seen at the end of in last trading. With action -8.49%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -4.77%, with the 5-day performance at -8.49% in the red. However, in the 30-day time frame, Biohaven Ltd (NYSE:BHVN) is -16.87% down. Looking at the short shares, we see there were 9.72 million shares sold at short interest cover period of 9.01 days.
The consensus price target for the stock as assigned by Wall Street analysts is 59, meaning bulls need an upside of 39.71% from its current market value. According to analyst projections, BHVN’s forecast low is 55 with 65 as the target high. To hit the forecast high, the stock’s price needs a -82.74% plunge from its current level, while the stock would need to soar -54.62% for it to hit the projected low.
Biohaven Ltd (BHVN) estimates and forecasts
Data shows that the Biohaven Ltd share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -7.49% over the past 6 months, a -54.45% in annual growth rate that is considerably lower than the industry average of 16.70%.
Consensus estimates given by 11 financial analysts project the company’s revenue in the current quarter to hit an average of 9.09M. 5 analysts are of the opinion that Biohaven Ltd’s revenue for the current quarter will be 2.5M. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at 0.00%.
The 2025 estimates are for Biohaven Ltd earnings to decrease by -57.00%.
BHVN Dividends
Biohaven Ltd is expected to release its next quarterly earnings report in February.
Biohaven Ltd (NYSE:BHVN)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 11.16% of Biohaven Ltd shares while 87.36% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 98.33%. There are 87.36% institutions holding the Biohaven Ltd stock share, with VANGUARD GROUP INC the top institutional holder. As of 2024-06-30, the company held 8.9114% of the shares, roughly 7.27 million BHVN shares worth $252.41 million.
STIFEL FINANCIAL CORP holds the second largest percentage of outstanding shares, with 7.9417% or 6.48 million shares worth $224.94 million as of 2024-06-30.
Among Mutual Funds, the top two as of Sep 30, 2024 were Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF . With 2.43 shares estimated at $86.5 million under it, the former controlled 2.40% of total outstanding shares. On the other hand, iShares Russell 2000 ETF held about 1.92% of the shares, roughly 1.94 shares worth around $68.88 million.
